P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 13.49 CNY -1.24% Market Closed
Market Cap: 4.6B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Pulike Biological Engineering Inc stock under the Base Case scenario is 13.84 CNY. Compared to the current market price of 13.49 CNY, Pulike Biological Engineering Inc is Undervalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
13.84 CNY
Undervaluation 3%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

4.2
P/S
P/S
Price to Sales
4.2
vs History
80
vs Industry
32
Median 3Y
5.5
Median 5Y
6.3
Industry
2.4
Forward
3.8
More Details
39
P/E
P/E
Price to Earnings
39
vs History
49
vs Industry
11
Median 3Y
43.8
Median 5Y
39.5
Industry
20.5
Forward
24.8
More Details
14.4
P/OCF
P/OCF
Price to OCF
14.4
vs History
95
vs Industry
23
Median 3Y
29
Median 5Y
29.5
Industry
15.6
More Details
18.6
P/FCFE
P/FCFE
Price to FCFE
18.6
vs History
52
vs Industry
11
Median 3Y
-47.1
Median 5Y
28.6
Industry
23.1
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
84
vs Industry
46
Median 3Y
2.7
Median 5Y
3.4
Industry
2
More Details
3.6
EV/S
EV/S
Enterprise Value to Sales
3.6
vs History
84
vs Industry
34
Median 3Y
4.8
Median 5Y
5.9
Industry
2.5
Forward
3.2
More Details
6.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.2
vs History
82
vs Industry
36
Median 3Y
7.9
Median 5Y
9.4
Industry
4.9
More Details
27.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.2
vs History
71
vs Industry
9
Median 3Y
35.3
Median 5Y
32.8
Industry
12.3
Forward
13.1
More Details
27.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.2
vs History
71
vs Industry
11
Median 3Y
35.3
Median 5Y
32.8
Industry
15.5
Forward
16.8
More Details
12.3
EV/OCF
EV/OCF
Enterprise Value to OCF
12.3
vs History
95
vs Industry
26
Median 3Y
25.3
Median 5Y
26.9
Industry
14.1
More Details
16
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16
vs History
52
vs Industry
11
Median 3Y
-42.3
Median 5Y
24.1
Industry
17.5
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
82
vs Industry
44
Median 3Y
2.9
Median 5Y
3.5
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Pulike Biological Engineering Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Pulike Biological Engineering Inc
SSE:603566
4.6B CNY 4.2 39 27.2 27.2
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.9 197.5
US
Merck & Co Inc
NYSE:MRK
192B USD 3 11 7.9 9.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
CN
P
Pulike Biological Engineering Inc
SSE:603566
Average P/E: 25.2
39
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
P
Pulike Biological Engineering Inc
SSE:603566
Average EV/EBITDA: 396.1
27.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
US
Merck & Co Inc
NYSE:MRK
7.9
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
P
Pulike Biological Engineering Inc
SSE:603566
Average EV/EBIT: 1 699.1
27.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
197.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.6
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.